Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation

Wang, Rui; Wang, Xiaoqi; Yang, Shijie; Xiao, Yunshuo; Jia, Yulin; Zhong, Jiangfan; Gao, Qiangguo; Zhang, Xi

doi:10.1016/j.jcyt.2021.07.009

Cited by 18 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Encouragingly, a retrospective study discovered an improved anti-leukemic effect of DLI after administration of G-CSF compared to conventional donor lymphocyte infusion (DLI) in patients who relapsed after allo-HCT, given that it was enriched in MDSCs and did not increase the cumulative GVHD incidence [ 126 ]. Furthermore, umbilical cord mesenchymal stem cells promote MDSCs enrichment and prevent GVHD after HSCT by secreting CXCL1 [ 127 ] and HLA-G [ 128 ]. Zhang et al investigated the inhibition of GVHD by MDSCs while preserving the GVL effect and noted that MDSCs induced NKG2D expression on T cells and simultaneously suppressed GVHD by upregulating Tregs [ 129 ].…”

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Ren

2022

Exp Hematol Oncol

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of bone marrow cells originating from immature myeloid cells. They exert potent immunosuppressive activity and are closely associated with the development of various diseases such as malignancies, infections, and inflammation. In malignant tumors, MDSCs, one of the most dominant cellular components comprising the tumor microenvironment, play a crucial role in tumor growth, drug resistance, recurrence, and immune escape. Although the role of MDSCs in solid tumors is currently being extensively studied, little is known about their role in hematologic malignancies. In this review, we comprehensively summarized and reviewed the different roles of MDSCs in hematologic malignancies and hematopoietic stem cell transplantation, and finally discussed current targeted therapeutic strategies.Affiliation: Kindly check and confirm the processed affiliations are correct. Amend if any.correct

show abstract

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Ren

2022

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…In this study, both M-MDSCs and G-MDSCs were elevated in PTCy treated mice from their GVHD model system and were similarly elevated in a cohort of primary allo-HCT patients ( 54 ). It has also been shown that umbilical cord blood is rich in MDSCs which may promote the low GVHD rates seen in cord blood transplants ( 56 ). Interestingly, the majority of studies that have found elevated MDSC frequencies have also found a similar increase in Tregs levels.…”

Section: The Role Of Mdscs In Controlling Gvhdmentioning

confidence: 99%

Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment

2023

View full text Add to dashboard Cite

The development of graft versus host disease (GVHD) represents a long-standing complication of allogeneic hematopoietic cell transplantation (allo-HCT). Different approaches have been used to control the development of GVHD with most relying on variations of chemotherapy drugs to eliminate allo-reactive T cells. While these approaches have proven effective, it is generally accepted that safer, and less toxic GVHD prophylaxis drugs are required to reduce the health burden placed on allo-HCT recipients. In this review, we will summarize the emerging concepts revolving around three biologic-based therapies for GVHD using T regulatory cells (Tregs), myeloid-derived-suppressor-cells (MDSCs) and mesenchymal stromal cell (MSC) exosomes. This review will highlight how each specific modality is unique in its mechanism of action, but also share a common theme in their ability to preferentially activate and expand Treg populations in vivo. As these three GVHD prevention/treatment modalities continue their path toward clinical application, it is imperative the field understand both the biological advantages and disadvantages of each approach.

show abstract

“…Mechanistic research comparing the efficacy of different tissue-derived MSCs in controlling GVHD found that human umbilical cord-derived mesenchymal stem cells (HUCMSCs) decrease GVHD more effectively by recruiting MDSCs to target tissues through the CXCL1–CXCR2 axis. [ 65 ] For cGVHD treatment, in Xinqiao Hospital, sirolimus combined with calcineurin inhibitor had a better effect on steroid-refractor (SR) cGVHD [ 66 ] with relatively mild side effects, and was thus suitable for long-term treatment of cGVHD. In addition, in SAA, co-transplantation with MSCs for haplo-HSCT is encouraging and is associated with high rates of engraftment and survival.…”

Section: Graft-versus-host Diseasementioning

confidence: 99%

Current status and prospects of hematopoietic stem cell transplantation in China

Wang

Huang

Zhang

et al. 2022

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a highly effective and unique medical procedure for the treatment of most hematological malignancies. The first allogeneic transplantation was performed by E. Donnall Thomas in 1957. Since then, the field has evolved and expanded worldwide. The first successful allogenic HSCT (allo-HSCT) in China was conducted in 1981. Although the development of allo-HSCT in China lagged, China has since made considerable contributions to the process of HSCT worldwide, with more than 10,000 HSCTs performed annually. In particular, haploid HSCT (haplo-HSCT) technology represented in the Beijing Protocol has demonstrated similar efficacy to human leukocyte antigen-matched HSCT and has gradually become the pre-dominant choice for allo-HSCT in China. Currently, the number of haplo-HSCT procedures exceeds 5000 per year, and the Beijing Protocol has been greatly improved by implementing updated individualized strategies for controlling complications, relapse, and infection management. In addition, innovative haplo-HSCT technologies developed by different medical transplantation centers, such as Soochow, Zhejiang, Fujian, Chongqing, and Anhui, have emerged, providing inspiration for the refinement of global practice. This review will focus on the current activity in this field and highlight important trends that are vital in China's allo-HSCT process, examining the current viewpoint and future directions.

show abstract

Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation

Cited by 18 publications

References 39 publications

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment

Current status and prospects of hematopoietic stem cell transplantation in China

Contact Info

Product

Resources

About